Women with single dose of HPV vaccine gain similar protection as multiple doses

A new study revealed that one dose of the HPV vaccine may prevent infection from the potential cancer-causing virus, according to research published inJAMA Network Open来自休斯敦的德克萨斯大学健康科学中心（Uthealth).

According to the Centers for Disease Control (CDC),34,800 new cancer diagnoses每年与人乳头瘤病毒（HPV）相关。该病毒被认为占所有宫颈和肛门癌的90％以上，超过60％的所有阴茎癌和大约70％的口服癌症。

While results of the paper showed that a single dose may be as effective as the currently recommended two- or three-dose series, it’s too early for people to rely on a single dose of the vaccine for protection, according to senior author Ashish A. Deshmukh, PhD, MPH, an assistant professor atUTHealth公共卫生学院.

“HPV vaccine coverage is less than 10% globally because of poor vaccine uptake rates in many resource-limited countries. Ensuring boys and girls receive their first dose is a big challenge in several countries and a majority of adolescents are not able to complete the recommended series due to a lack of intensive infrastructure needed to administer two or three doses,” Deshmukh said. “If ongoing clinical trials provide evidence regarding sustained benefits of a one-dose regimen, then implications of single-dose strategy could be substantial for reducing the burden of these cancers globally.”

Although the study participants included only women, the CDC recommends a two-dose regimen for all children starting the series before age 15 or a three-dose regimen if the series is started between ages 16 to 26. The latest generation of HPV vaccine can protect against nearly 90% of cancer-causing HPV infections. Yet, current vaccinations rates are less than ideal –美国一半的人未接种疫苗反对这种常见的性传播感染。

“The current HPV vaccine dosing regimen can be cumbersome for people to understand. If one dose is proven effective in trials, the vaccine regimen will be simplified. This will help improve the coverage rate among adolescents that are currently below the Healthy People 2020 goal and possibly will also increase the momentum of uptake in the newly approved age group,” said lead author Kalyani Sonawane, PhD, who is an assistant professor at UTHealth School of Public Health.

Michael D. Swartz, PhD, of UTHealth co-authored the study, along with Alan G. Nyitray, PhD, of the Medical College of Wisconsin; and Gizem S. Nemutlu, PhD, and Jagpreet Chhatwal, PhD, from Harvard Medical School.

Research was supported by the National Cancer Institute of the National Institutes of Health (R01CA232888). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Media Inquiries – 713-500-3030